LR11/SorLA links triglyceride-rich lipoproteins to risk of developing cardiovascular disease in FH patients

• We investigated the involvement of LR11 and sLR11 in CVD development in FH patients.
• In asymptomatic male heterozygous FH subjects plasma sLR11 correlates with C-IMT.
• Increased plasma sLR11 and hepatic LR11 in Ldlr−/− mice after high-fat feeding.
• TGRL bind LR11 and upregulate LR11 mRNA and protein and sLR11 release from HASMC.
• Our data suggest LR11 mediates harmful effects of a HFD on CVD progression.

ObjectiveFamilial Hypercholesterolemia (FH) is associated with an increased risk of cardiovascular disease (CVD). However, whether an individual heterozygous FH patient will develop CVD depends on other genetic- and environmental risk factors as well. LDL receptor-related protein with 11 ligand binding repeat (LR11) and its soluble form (sLR11) play a role in the progression of atherosclerosis. We investigated the involvement of LR11 and sLR11 in CVD development in FH patients and in LDLR deficient (Ldlr−/−) mice.Approach and resultsIn statin-treated asymptomatic male heterozygous FH subjects, plasma sLR11 levels correlated with carotid intima-media thickness. Increased plasma sLR11 levels were found in Ldlr−/− and also in wild-type mice exclusively after high-fat feeding. Hepatic LR11 mRNA levels, however, were higher in chow-fed Ldlr−/− in comparison with wild-type mice and were further increased after a high fat diet. Similar results were obtained with Apoe−/− mice, but not with wild-type mice. LR11 mRNA and protein levels and release of sLR11 from cultured HepG2 and aortic smooth muscle cells were upregulated by postprandial triglyceride-rich lipoproteins (TGRL). Overexpression of human LR11 in CHO cells resulted in increased binding and association of 12I-labeled TGRL, but not of 12I-labeled LDL.ConclusionOur data strongly suggest an involvement of LR11 in mediating the harmful effects of a high-fat diet on CVD progression. Elevated sLR11 levels may increase the CVD risk especially in subjects with delayed clearance of triglyceride-rich remnants, such as in FH patients.

Figure optionsDownload high-quality image (117 K)Download as PowerPoint slide